Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 12:18 PM
Ignite Modification Date:
2025-12-24 @ 12:18 PM
NCT ID:
NCT04174261
Eligibility Criteria:
Inclusion Criteria:
* Provision of informed consent prior to any study specific procedures
* Patients (Female and male) ≥ 18 of age
* Patients with NSTE-ACS undergoing coronary angiography, eligible for PCI
Exclusion Criteria:
* Women of childbearing potential
* Severe comorbidity (estimated life expectancy \<6 months)
* Baseline cTnI before PCI that is not stable or falling or is \> 5 ×99th percentile URL.
* End-stage renal disease(eGFR\<15 ml/min/1.73 m2)
* CRUSADE Bleeding Score \>50
* Patients with an indication for oral anticoagulation
* On maintenance therapy with ticagrelor or those that have received clopidogrel for less than 3 days
* Use of nicorandil or glibenclamide
* Concomitant theophylline/aminophylline use
* Known contraindications to the use of ticagrelor Hypersensitivity to the active substance or to any of the excipients
* Active pathological bleeding
* History of intracranial haemorrhage
* Moderate to severe hepatic impairment
* Co-administration of ticagrelor with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir).
* Patients meeting criteria for immediate or early (\<24h) invasive strategy based on the current relevant European Society of Cardiology guidelines
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04174261
Study Brief:
Protocol Section:
NCT04174261